Skip to search formSkip to main contentSkip to account menu

Ursodiol

Known as: Acid, Ursodeoxycholic, 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid, (3?,5?,7?)-3,7-dihydroxycholan-24-oic acid 
A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder. Also produced by the Chinese… 
National Institutes of Health

Related topics

Related topics

42 relations

Narrower (25)

23-methylursodeoxycholic acid24-norursodeoxycholic acid3,6-dihydroxy-6-methylcholanoic acid6-fluoro-ursodeoxycholic acid
Bile Acids and SaltsBiliary cirrhosisCholelithiasisDrug Allergy

Broader (2)

Cholagogues and CholereticsUrsodeoxycholate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
Highly Cited
2006
Highly Cited
2006
Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes
Endoplasmic reticulum (ER) stress is a key link between obesity, insulin resistance, and type 2 diabetes. Here, we provide… 
Review
2004
Review
2004
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA… 
Review
2002
Review
2002
Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence suggests… 
Highly Cited
2001
Highly Cited
2001
Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis
Patients with ulcerative colitis have an increased risk for colorectal neoplasia; this risk approaches 0.5% to 1% per year of… 
Review
2000
Review
2000
[Primary sclerosing cholangitis].
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by fibrosing inflammation and… 
Review
1999
Review
1999
The continuing importance of bile acids in liver and intestinal disease.
Bile acids, the water-soluble, amphipathic end products of cholesterol metabolism, are involved in liver, biliary, and intestinal… 
Highly Cited
1997
Highly Cited
1997
Ursodiol for Primary Sclerosing Cholangitis
Background There is no satisfactory medical therapy for patients with primary sclerosing cholangitis. Ursodiol (ursodeoxycholic… 
Highly Cited
1994
Highly Cited
1994
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.
BACKGROUND Ursodiol (ursodeoxycholic acid) therapy leads to major improvements in patients with primary biliary cirrhosis. The… 
Highly Cited
1991
Highly Cited
1991
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
BACKGROUND In primary biliary cirrhosis the hepatic lesions may result, at least in part, from the intracellular accumulation of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)